2020
DOI: 10.1016/j.msec.2019.110332
|View full text |Cite
|
Sign up to set email alerts
|

Doxorubicin eluting microporous polysaccharide scaffolds: An implantable device to expunge tumour

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
21
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
4
2

Relationship

0
6

Authors

Journals

citations
Cited by 12 publications
(21 citation statements)
references
References 45 publications
0
21
0
Order By: Relevance
“…The encouraging observation from the in vitro cytotoxicity studies in 2-D and 3-D culture models urged us to investigate the in vivo antitumor potential of DOX@CM-PIONPs. Dalton Lymphoma Ascites (DLA) tumor model is an established syngeneic tumor model 20 . Here we had used a lower concentration of nanoparticles (equivalent dose of 2.5 mg/kg DOX) to avoid non-specific bio-distribution and systemic toxicity.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…The encouraging observation from the in vitro cytotoxicity studies in 2-D and 3-D culture models urged us to investigate the in vivo antitumor potential of DOX@CM-PIONPs. Dalton Lymphoma Ascites (DLA) tumor model is an established syngeneic tumor model 20 . Here we had used a lower concentration of nanoparticles (equivalent dose of 2.5 mg/kg DOX) to avoid non-specific bio-distribution and systemic toxicity.…”
Section: Resultsmentioning
confidence: 99%
“…Recent progress in 3D cell culture models enabled researchers to replicate the tumor microarchitecture composed of cancer foci within a reactive stroma, which is populated by non-cancer cells such as fibroblasts and endothelial cells in supporting tumor growth and potential drug response 19 , 20 . Due to the excessive expenditure in the development and the generation of drug delivery systems along with undesired side effects and long-term health risks, nanoformulation for the treatment of malignant tumors has the lowermost grant in the drug development scenario.…”
Section: Introductionmentioning
confidence: 99%
“…Preethi et al reported a galactoxyloglucanbased porous hydrogel scaffold with a high porosity of 90% by crosslinking and freeze drying, and chemotherapeutic drug DOX was loaded in the scaffold. [27] The DOX-loaded scaffolds exhibited higher DOX release rate in weakly acidic solution similar to tumor microenvironment (TME) than normal physiological microenvironment, thus preventing systemic toxicity. [27] Furthermore, in vivo tumor therapy studies showed that 77% of tumor size was reduced within 2 days and gradually reduced up to 96% after the implantation.…”
Section: Biomaterials Scaffolds With Local Drug Delivery For Tumor Thementioning
confidence: 99%
“…[27] Furthermore, in vivo tumor therapy studies showed that 77% of tumor size was reduced within 2 days and gradually reduced up to 96% after the implantation. [27] All these results revealed that the DOXloaded hydrogel scaffolds have great potential for combining chemotherapy and bone regeneration. Similarly, Bischoff et al developed a cyclodextrin-coated HA scaffold containing DOX.…”
Section: Biomaterials Scaffolds With Local Drug Delivery For Tumor Thementioning
confidence: 99%
See 1 more Smart Citation